Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RecruitingPhase 3
Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
About the study
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
What is being tested
- Gen 2 Travoprost Intracameral Implant (drug)
- Timolol eye drops 0.5% (drug)
- Sham Procedure (procedure)
- placebo eye drops (other)
Sponsor: Glaukos Corporation · Participants: 510 · Started: Feb 17, 2026
Contact the study team
- Study Director · Phone: 949-739-8749
Official record on ClinicalTrials.gov — NCT07495852
Locations in the U.S.
| Alabama | Glaukos Investigative Site, Dothan |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.